In collaboration with DataRobot, FOXO will utilise the predictive AI’s capabilities and high-throughput automation to predict factors related to human longevity using epigenetic biomarkers
FOXO collaborates with DataRobot for epigenetic biomarker research. (Credit: Steve Johnson on Unsplash)
Biotechnology company FOXO Technologies has partnered with US-based DataRobot for artificial intelligence (AI)-based epigenetic biomarker research in human longevity.
Under the partnership, both firms will use epigenetics and AI to generate data-driven insights that help optimal health and longevity.
In collaboration with DataRobot, a Value-Driven AI firm, FOXO will utilise the predictive AI’s capabilities and high-throughput automation to predict factors related to human longevity using epigenetic biomarkers.
FOXO Technologies CEO Tyler Danielson said: “We believe that with the ability to analyse data at scale, FOXO can uncover critical patterns and associations that hold the potential to reshape healthcare and wellness strategies.
“Our mission is to enhance human health and longevity through innovative technologies. Collaborating with DataRobot has given us the tools to accelerate our efforts, providing crucial insights into the ageing process and ultimately enabling us to improve the quality of life for people worldwide.”
According to the biotechnology company, epigenetic indicators shed light on the connections between human longevity, ageing, and health. These biomarkers are created using DNA methylation microarray technology, which examines over 860,000 locations on the human genome.
FOXO is commercialising these epigenetic biomarkers by automating the training and assessment of thousands of models for their use in customised wellness and disease prevention.
The collaboration between both parties is expected to support this research.
By using the AI platform of DataRobot, FOXO can effectively analyse enormous amounts of complex data, thus accelerating the discovery of important biomarkers.
Incorporating AI and machine learning will allow the company to maintain its position in the epigenetic research sector and provide clients with speed and computational power, according to the biotechnology firm.
FOXO Technologies Bioinformatics and Data Science director Nichole Rigby said: “This partnership has been transformative for our research.
“DataRobot’s library of advanced algorithms and extensive automation capabilities have empowered us to rapidly transform DNA methylation data into useful insights, enabling us to develop and deploy software products quickly.”